Outlook Therapeutics, Inc. Share Price & Technical Analysis
OTLK · $0.31 (-6.06%)
Healthcare / Biotechnology
$0.31
-6.06%
Outlook Therapeutics, Inc., operates as a clinical-stage biopharmaceutical company, focuses on developing and commercializing monoclonal antibodies for ophthalmic indications. Its lead product candidate is ONS-5010, an ophthalmic bevacizumab product formulation of bevacizumab product candidate that is in Phase-III clinical trial for the treatment of wet age-related macular degeneration and other r…
Price chart
Seasonality
May has 2 positive and 2 negative years (last 5 years shown)
0% return in May, 11% avg return in past 3 year May month.
-83% return in 2026, 10% avg return in past 3 years.
Swipe sideways to see all months →
| Jan | Feb | Mar | Apr | May | Jun | Jul | Aug | Sep | Oct | Nov | Dec | Yr | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 26 | -33% | 0% | -50% | 0% | 0% | – | – | – | – | – | – | – | -83% |
| 25 | 11% | -25% | -25% | 33% | 13% | -16% | 25% | -55% | 22% | 30% | 38% | -11% | 40% |
| 24 | -5% | 12% | 35% | -28% | -20% | 4% | 5% | -6% | -27% | 5% | -66% | -10% | -100% |
| 23 | 6% | -6% | -2% | -5% | 40% | 15% | -1% | -87% | -6% | 173% | -19% | -17% | 91% |
| 22 | 2% | 16% | 8% | -14% | -26% | -6% | 11% | 0% | 9% | -6% | -10% | 4% | -13% |
Monthly return % by calendar month · historical pattern, not a forecast
Neutral · Downtrend · Strong
Outlook Therapeutics, Inc., operates as a clinical-stage biopharmaceutical company, focuses on developing and commercializing monoclonal antibodies for ophthalmic indications. Its lead product candidate is ONS-5010, an ophthalmic bevacizumab product formulation of bevacizumab product candidate that is in Phase-III clinical trial for the treatment of wet age-related macular degeneration and other retina diseases. Outlook Therapeutics, Inc. has collaboration agreements with Cencora. Outlook Therapeutics, Inc. was formerly known as Oncobiologics, Inc. and changed its name to Outlook Therapeutics, Inc. in November 2018. Outlook Therapeutics, Inc. was incorporated in 2010 and is based in Iselin, New Jersey.
Full AI Q&A, portfolio tracking, and live alerts in the app.
Key metrics
Market cap
$27.44M
P/E ratio
—
52W high
$3.39
52W low
$0.16
Volume
83,40,088
Beta
0.33
Related stocks in Healthcare
Merck & Co Inc Cedear (5…
₹32,900
Abbott Laboratories Cede…
₹30,500
Eli Lilly And Company Ce…
₹25,540
Unitedhealth Group Inc C…
₹17,200
₹6,600
Frequently asked questions
- What is Outlook Therapeutics, Inc. share price today?
- Outlook Therapeutics, Inc. (OTLK) last traded around $0.31 on StockPro. Prices refresh every few minutes during market hours.
- What technical signals does OTLK have?
- StockPro monitors breakouts, volume spikes, EMA reversals, and momentum for OTLK. Download the app for real-time alerts.
- How can I analyze Outlook Therapeutics, Inc. stock?
- Use the price chart, seasonality heatmap, key metrics, and AI insight on this page. For portfolio tracking and push alerts, download StockPro on Android or iOS.